Showing results (31-40 of 44) with videos related to
Sort By:
Pageof 5
Blood Advances|June 30, 2026
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin LymphomaSimon Leiders, Dominic Ufton, Helen Kaul, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 8, 2021
PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter StudyJustin Ferdinandus, Wolfgang P Fendler, Andrea Farolfi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesWolfgang P Fendler, Kim M Pabst, Lukas Kessler, et al.Haematologica|February 26, 2026
Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysisHishan Tharmaseelan, Lisa M Sgonina, Ina Bühnen, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 16, 2023
68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational TrialLukas Kessler, Nader Hirmas, Kim M Pabst, et al.Cancer|October 18, 2025
Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survivalKemal Caglar Gogebakan, Zizi Elsisi, Felipe Montano-Campos, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 3, 2020
Impact of 68Ga-PSMA-11 PET on the Management of Recurrent Prostate Cancer in a Prospective Single-Arm Clinical TrialWolfgang P Fendler, Justin Ferdinandus, Johannes Czernin, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2019
Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate CancerJohn Violet, Shahneen Sandhu, Amir Iravani, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 25, 2023
68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective StudyRiccardo Mei, Lukas Kessler, Kim M Pabst, et al.Blood|February 9, 2026
MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assayJan-Michel Heger, Julia Mattlener, Helen Kaul, et al.Pageof 5